Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours

TA265 Bone metastases from solid tumours - denosumab: review proposal - July 2013 information

TA265 Bone metastases from solid tumours - denosumab: Appendix A provisional matrix of stakeholders

TA265 Bone metastases from solid tumours - denosumab: Appendix A provisional matrix of stakeholders (PDF 104 KB)

TA265 Bone metastases from solid tumours - denosumab: Appendix B proposal paper presented to the Institute's Guidance Executive

TA265 Bone metastases from solid tumours - denosumab: Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 334 KB)

Bone metastases from solid tumours - denosumab: EIA guidance development

Bone metastases from solid tumours - denosumab: appeal announcement information

Bone metastases from solid tumours - denosumab: appeal from Prostate Cancer Support Federation

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation - appeal received

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation - appeal received (PDF 203 KB)

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation - initial scrutiny letter

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation - initial scrutiny letter (PDF 82 KB)

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation - response to scrutiny letter

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation - response to scrutiny letter (PDF 47 KB)

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation - final scrutiny letter

Bone metastases from solid tumours - denosumab: final appraisal determination  information

Bone metastases from solid tumours - denosumab: final appraisal determination guidance

Bone metastases from solid tumours - denosumab: final appraisal determination guidance (PDF 332 KB)

Bone metastases from solid tumours - denosumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Bone metastases from solid tumours - denosumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 228 KB)

Bone metastases from solid tumours - denosumab: Consultee and commentator comments on the ACD

Bone metastases from solid tumours - denosumab: Amgen (manufacturer)

Bone metastases from solid tumours - denosumab: Amgen (manufacturer) (PDF 348 KB)

Bone metastases from solid tumours - denosumab: British Uro-Oncology group

Bone metastases from solid tumours - denosumab: British Uro-Oncology group (PDF 259 KB)

Bone metastases from solid tumours - denosumab: Royal College of Nursing

Bone metastases from solid tumours - denosumab: Royal College of Nursing (PDF 58 KB)

Bone metastases from solid tumours - denosumab: Royal College of Physicians

Bone metastases from solid tumours - denosumab: Royal College of Physicians (PDF 223 KB)

Bone metastases from solid tumours - denosumab: Healthcare Improvement Scotland

Bone metastases from solid tumours - denosumab: Healthcare Improvement Scotland (PDF 27 KB)

Bone metastases from solid tumours - denosumab: Prostate Action

Bone metastases from solid tumours - denosumab: Prostate Action (PDF 182 KB)

Bone metastases from solid tumours - denosumab: Comments on the ACD received from the public through the NICE website

Bone metastases from solid tumours - denosumab: appraisal consultation 2

Bone metastases from solid tumours - denosumab: evaluation report

Bone metastases from solid tumours - denosumab: consultee and commentator comments on the ACD

Bone metastases from solid tumours - denosumab: Amgen

Bone metastases from solid tumours - denosumab: Amgen (PDF 119 KB)

Bone metastases from solid tumours - denosumab: Breakthrough Breast Cancer

Bone metastases from solid tumours - denosumab: Breakthrough Breast Cancer (PDF 140 KB)

Bone metastases from solid tumours - denosumab: British Uro-oncology Group

Bone metastases from solid tumours - denosumab: British Uro-oncology Group (PDF 71 KB)

Bone metastases from solid tumours - denosumab: Royal College of Physicians

Bone metastases from solid tumours - denosumab: Royal College of Physicians (PDF 338 KB)

Bone metastases from solid tumours - denosumab: National Collaborating Centre for Cancer

Bone metastases from solid tumours - denosumab: National Collaborating Centre for Cancer (PDF 138 KB)

Bone metastases from solid tumours - denosumab: comments on the ACD received from the public through the NICE website.

Bone metastases from solid tumours - denosumab: comments on the ACD received from the public through the NICE website. (PDF 37 KB)

Bone metastases from solid tumours - denosumab: Assessment Group response to Amgen's comment 2.2 in response to the ACD

Bone metastases from solid tumours - denosumab: Assessment Group response to Amgen's comment 2.2 in response to the ACD (PDF 155 KB)

Bone metastases from solid tumours - denosumab: appraisal consultation document information

Denosumab for prolonging bone metastasis-free survival in hormone-refractory prostate cancer information

Bone metastases (hormone refractory prostate cancer) - denosumab: final matrix

Bone metastases (hormone refractory prostate cancer) - denosumab: final matrix (PDF 33 KB)

Bone metastases (hormone refractory prostate cancer) - denosumab: final scope

Bone metastases (hormone refractory prostate cancer) - denosumab: final scope (PDF 95 KB)

Bone metastases (hormone refractory prostate cancer) - denosumab: response to comments on the draft scope and provisional matrix

Bone metastases (hormone refractory prostate cancer) - denosumab: response to comments on the draft scope and provisional matrix (PDF 148 KB)

Prostate cancer (castrate-resistant) - denosumab (bone metastasis): provisional matrix (post referral)

Prostate cancer (castrate-resistant) - denosumab (bone metastasis): provisional matrix (post referral) (PDF 57 KB)

Prostate cancer (castrate-resistant) - denosumab (bone metastasis): draft scope (post referral)

Prostate cancer (castrate-resistant) - denosumab (bone metastasis): draft scope (post referral) (PDF 54 KB)

Prostate cancer (castrate-resistant) - denosumab (bone metastasis): appendix B - draft scope for consultation (pre-referral) July 2011

Prostate cancer (castrate-resistant) - denosumab (bone metastasis): appendix B - draft scope for consultation (pre-referral) July 2011 (PDF 63 KB)

Prostate cancer (castrate-resistant) - denosumab (bone metastasis): appendix C - provisional matrix (pre-referral) July 2011

Prostate cancer (castrate-resistant) - denosumab (bone metastasis): appendix C - provisional matrix (pre-referral) July 2011 (PDF 57 KB)

Prostate cancer: diagnosis and treatment (update) information

Prostate cancer: guideline development and consultation

Prostate cancer: equality impact assessment (guideline development)

Prostate cancer: equality impact assessment (guideline development) (PDF 191 KB)

Prostate cancer: draft guideline consultation comments

Prostate cancer: draft guideline consultation comments (PDF 978 KB)

Prostate cancer (update): guideline consultation information

Prostate cancer (update): draft guideline

Prostate cancer (update): draft guideline (PDF 3.84 MB)

Prostate cancer (update): appendices J - L

Prostate cancer (update): appendices J - L (PDF 1.85 MB)

Prostate cancer (update): evidence review

Prostate cancer (update): evidence review (PDF 13.77 MB)

registered stakeholder organisation

Prostate cancer update: list of registered stakeholders (PDF 53 KB)

Prostate cancer (update): economic plan

Prostate cancer (update): economic plan (PDF 71 KB)

Prostate cancer (update): search strategies

Prostate cancer (update): search strategies (PDF 427 KB)

Prostate cancer (update): clinical questions

Prostate cancer (update): clinical questions (PDF 166 KB)

Prostate cancer: GDG minutes

GDG 11: 30 September - 1 October 2013

GDG 11: 30 September - 1 October 2013 (PDF 72 KB)

GDG 10: 1-2 May 2013

GDG 10: 1-2 May 2013 (PDF 77 KB)

GDG 9: 19-20 March 2013

GDG 9: 19-20 March 2013 (PDF 89 KB)

GDG 8: 1 February 2013

GDG 8: 1 February 2013 (PDF 74 KB)

GDG 7: 13 December 2012

GDG 7: 13 December 2012 (PDF 90 KB)

GDG 6: 23-24 October 2012

GDG 6: 23-24 October 2012 (PDF 133 KB)

GDG 5: 4 September 2012

GDG 5: 4 September 2012 (PDF 46 KB)

GDG 4: 16 July 2012

GDG 4: 16 July 2012 (PDF 44 KB)

GDG 3: 18 May 2012

GDG 3: 18 May 2012 (PDF 60 KB)

GDG 2: 3 April 2012

GDG 2: 3 April 2012 (PDF 73 KB)

GDG 1: 8-9 February 2012

GDG 1: 8-9 February 2012 (PDF 20 KB)

Prostate cancer update: membership list

Prostate cancer update: membership list (PDF 23 KB)

Prostate cancer update: scoping workshop, consultation and final scope

Prostate cancer update: equality impact assessment (scoping)

Prostate cancer update: equality impact assessment (scoping) (PDF 159 KB)

Prostate cancer update: scope consultation information

Prostate cancer update: draft scope

Prostate cancer update: draft scope (PDF 90 KB)

Prostate cancer update: scope consultation table

Prostate cancer update: scope consultation table (PDF 717 KB)

Prostate cancer update: final scope

Prostate cancer update: final scope (PDF 89 KB)

ply. If you information

Bone metastases from solid tumours - denosumab: Dr David Dodds

Bone metastases from solid tumours - denosumab: appraisal consultation

Bone metastases from solid tumours - denosumab: appraisal consultation document information

Bone metastases from solid tumours - denosumab: evaluation report

Bone metastases from solid tumours - denosumab: overview

Bone metastases from solid tumours - denosumab: overview (PDF 430 KB)

Bone metastases from solid tumours - denosumab: assessment report

Bone metastases from solid tumours - denosumab: assessment report

Bone metastases from solid tumours - denosumab: assessment report (PDF 2.75 MB)

Bone metastases from solid tumours - denosumab: assessment report appendices

Bone metastases from solid tumours - denosumab: assessment report appendices (PDF 2.11 MB)

Bone metastases from solid tumours - denosumab: assessment report erratum

Bone metastases from solid tumours - denosumab: assessment report erratum (PDF 1.52 MB)

Bone metastases from solid tumours - denosumab: consultee and commentator comments on the assessment report

Bone metastases from solid tumours - denosumab: Amgen

Bone metastases from solid tumours - denosumab: Amgen (PDF 271 KB)

Bone metastases from solid tumours - denosumab: Royal College of Physicians

Bone metastases from solid tumours - denosumab: Royal College of Physicians (PDF 227 KB)

Bone metastases from solid tumours - denosumab: Healthcaree Improvement Scotland

Bone metastases from solid tumours - denosumab: Healthcaree Improvement Scotland (PDF 24 KB)

Bone metastases from solid tumours - denosumab: Novartis

Bone metastases from solid tumours - denosumab: Novartis (PDF 58 KB)

Bone metastases from solid tumours - denosumab: National Collaborating Centre for Cancer

Bone metastases from solid tumours - denosumab: National Collaborating Centre for Cancer (PDF 235 KB)

Bone metastases from solid tumours - denosumab: response to consultee and commentator comments on the assessment report

Bone metastases from solid tumours - denosumab: response to consultee and commentator comments on the assessment report (PDF 312 KB)

Bone metastases from solid tumours - denosumab: manufacturer submissions (executive summary only)

Bone metastases from solid tumours - denosumab: Amgen executive summary

Bone metastases from solid tumours - denosumab: Amgen executive summary (PDF 153 KB)

Bone metastases from solid tumours - denosumab: Amgen PAS template

Bone metastases from solid tumours - denosumab: Amgen PAS template (PDF 1.23 MB)

Bone metastases from solid tumours - denosumab: non-manufacturer submission

Bone metastases from solid tumours - denosumab: Breast Cancer Care

Bone metastases from solid tumours - denosumab: Breast Cancer Care (PDF 93 KB)

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation

Bone metastases from solid tumours - denosumab: Prostate Cancer Support Federation (PDF 45 KB)

Bone metastases from solid tumours - denosumab: Royal College of Physicians

Bone metastases from solid tumours - denosumab: Royal College of Physicians (PDF 144 KB)

Bone metastases from solid tumours - denosumab: expert written personal statements

Bone metastases from solid tumours - denosumab: Bhal

Bone metastases from solid tumours - denosumab: Bhal (PDF 74 KB)

Bone metastases from solid tumours - denosumab: Beaumont

Bone metastases from solid tumours - denosumab: Beaumont (PDF 104 KB)

Bone metastases from solid tumours - denosumab: Dodds (clinical)

Bone metastases from solid tumours - denosumab: Dodds (clinical) (PDF 74 KB)

Bone metastases from solid tumours - denosumab: Dodds (patient)

Bone metastases from solid tumours - denosumab: Dodds (patient) (PDF 75 KB)

Bone metastases from solid tumours - denosumab: Harland

Bone metastases from solid tumours - denosumab: assessment report 

Bone metastases from solid tumours - denosumab: assessment report appendices 

Bone metastases from solid tumours and multiple myeloma - denosumab: EIA form

Bone metastases from solid tumours and multiple myeloma - denosumab: final protocol

Bone metastases from solid tumours and multiple myeloma - denosumab: final scope

Bone metastases from solid tumours and multiple myeloma - denosumab: final matrix

Bone metastases from solid tumours and multiple myeloma - denosumab: provisional matrix

Bone metastases from solid tumours and multiple myeloma - denosumab: draft scope